Literature DB >> 11386415

Differential expression of somatostatin receptors in medulloblastoma.

J Guyotat1, J Champier, G S Pierre, A Jouvet, P Bret, C Brisson, M F Belin, F Signorelli, M F Montange.   

Abstract

OBJECT: Somatostatin receptors have been found on a variety of tumours like neuroendocrine breast or brain tumours. Their detection opens new diagnostic and therapeutic paths. The aim of this work was to investigate their expression in medulloblastomas.
METHODS: Using both techniques, reverse transcriptase-polymerase chain reaction and immunohistochemistry, we analysed mRNA of different subtypes of somatostatin receptors in 15 medulloblastomas and the localisation of the subtype SSTR2 receptor at the cellular level in 13 medulloblastomas. All five subtypes mRNA were variably expressed in each medulloblastoma. The signal obtained after Southern blotting for SSTR2 receptor amplification was the highest as compared to the signal obtained for the other receptor subtypes. Immunostaining for SSTR2A receptor was present in every tumour specimen and was specifically located to the cellular membrane of neoplastic cells. No staining was identified at the level of peritumoral veins.
CONCLUSION: The evidence of predominant expression of SSTR2 receptors in medulloblastomas opens interesting prospects for their diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11386415     DOI: 10.1023/a:1010624702443

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  39 in total

1.  Time-dependent influence of the somatostatin analogue octreotide on the proliferation of rat astrocytes and glioma cells.

Authors:  J Feindt; R Mentlein; B Krisch
Journal:  Brain Res       Date:  1997-01-23       Impact factor: 3.252

Review 2.  Primitive neuroectodermal tumors of the central nervous system.

Authors:  L B Rorke; J Q Trojanowski; V M Lee; R A Zimmerman; L N Sutton; J A Biegel; J W Goldwein; R J Packer
Journal:  Brain Pathol       Date:  1997-04       Impact factor: 6.508

3.  Expression of five somatostatin receptor mRNAs in the human brain and pituitary.

Authors:  V S Thoss; J Pérez; A Probst; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 4.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

Review 5.  Molecular biology of somatostatin receptor subtypes.

Authors:  Y C Patel; M Greenwood; R Panetta; N Hukovic; S Grigorakis; L A Robertson; C B Srikant
Journal:  Metabolism       Date:  1996-08       Impact factor: 8.694

6.  High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy.

Authors:  M C Frühwald; M S O'Dorisio; T Pietsch; J C Reubi
Journal:  Pediatr Res       Date:  1999-05       Impact factor: 3.756

7.  The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization.

Authors:  M Vanetti; G Vogt; V Höllt
Journal:  FEBS Lett       Date:  1993-10-04       Impact factor: 4.124

8.  Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors.

Authors:  S J Qualman; M S O'Dorisio; D J Fleshman; H Shimada; T M O'Dorisio
Journal:  Cancer       Date:  1992-10-01       Impact factor: 6.860

Review 9.  Prognostic factors in medulloblastoma.

Authors:  M T Giordana; P Schiffer; D Schiffer
Journal:  Childs Nerv Syst       Date:  1998-06       Impact factor: 1.475

10.  Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies.

Authors:  S Schulz; S Schulz; J Schmitt; D Wiborny; H Schmidt; S Olbricht; W Weise; A Roessner; C Gramsch; V Höllt
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

View more
  9 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  Differential somatostatin receptor subtype expression in human normal pineal gland and pineal parenchymal tumors.

Authors:  J Champier; A Jouvet; C Rey; J Guyotat; M Fevre-Montange
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

Review 3.  Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management.

Authors:  Margot A Lazow; Joshua D Palmer; Maryam Fouladi; Ralph Salloum
Journal:  Neurotherapeutics       Date:  2022-07-20       Impact factor: 6.088

4.  Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma.

Authors:  Marc Remke; Esther Hering; Nicolas U Gerber; Marcel Kool; Dominik Sturm; Christian H Rickert; Joachim Gerß; Stefan Schulz; Thomas Hielscher; Martin Hasselblatt; Astrid Jeibmann; Volkmar Hans; Vijay Ramaswamy; Michael D Taylor; Torsten Pietsch; Stefan Rutkowski; Andrey Korshunov; Carmelia-Maria Monoranu; Michael C Frühwald
Journal:  Childs Nerv Syst       Date:  2013-05-16       Impact factor: 1.475

5.  Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.

Authors:  Chien-Tsun Kuan; Carol J Wikstrand; Roger E McLendon; Michael R Zalutsky; Ujendra Kumar; Darell D Bigner
Journal:  Hybridoma (Larchmt)       Date:  2009-12

6.  [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.

Authors:  Ganesan Vaidyanathan; Donna J Affleck; Xiao-Guang Zhao; Stephen T Keir; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2010

Review 7.  How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology.

Authors:  Arian Lasocki; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2019-08-19       Impact factor: 3.909

Review 8.  The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer.

Authors:  Alex J Poot; Marnix G E H Lam; Max M van Noesel
Journal:  Front Oncol       Date:  2020-11-19       Impact factor: 6.244

Review 9.  Posterior fossa extra-axial variations of medulloblastoma: a pictorial review as a primer for radiologists.

Authors:  Abdulaziz M Al-Sharydah; Abdulrahman Hamad Al-Abdulwahhab; Sari Saleh Al-Suhibani; Wisam M Al-Issawi; Faisal Al-Zahrani; Faisal Ahmad Katbi; Moath Abdullah Al-Thuneyyan; Tarek Jallul; Faisal Mishaal Alabbas
Journal:  Insights Imaging       Date:  2021-04-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.